News

Biocon announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Biocon declined 63.45% to Rs 125.90 crore in the quarter ended March 2026 as against Rs 344.50 crore during the previous quarter ended March 2025. Sales rose 2.90% to Rs 4484.30 crore in the quarter ended March 2026 as against Rs 4358.10 crore during the previous quarter ended March 2025.For the full year,net profit declined 61.95% to Rs 385.60 crore in the year ended March 2026 as against Rs 1013.30 crore during the previous year ended March 2025. Sales rose 11.48% to Rs 16779.90 crore in the year ended March 2026 as against Rs 15052.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales4484.304358.10 3 16779.9015052.20 11 OPM %22.7524.74 -20.5921.04 - PBDT841.30902.70 -7 2807.503477.10 -19 PBT327.90466.40 -30 850.801790.10 -52 NP125.90344.50 -63 385.601013.30 -62 Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya� (denosumab), a biosimilar to Prolia�, and Vezuo� (denosumab), a biosimilar to Xgeva�, on 03 April 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial. Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.Shreehas Tambe, CEO & Managing Director, Biocon, said, �Health Canada`s approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets. This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.�

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Mukesh Kamath, tendered vide his letter dated 20 March 2026, from the position of Interim Chief Financial Officer of the Company with effect from close of business hours of 31 March 2026 to take up another role within the Biocon Group.Further, the board has approved the appointment of Kedar Narayan Upadhye, Chief Financial Officer of Biocon Biologics, as the Chief Financial Officer (Key Managerial Personnel and Senior Management Personnel) of the Company, with effect from 01 April 2026. Powered by Capital Market - Live News